Out of every 20 reported cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ, ONJ, or BON), only 1 of those 20 cases involved the use of bisphosphonates for the treatment or prevention of osteopenia or osteoporosis. The other 19 cases involved the use of bisphosphonates for the treatment of various cancers. Between 5% and 11% of all patients treated for cancer (with high-dose intravenous bisphosphonates) developed osteonecrosis of the jaw, while the rate for patients treated for osteopenia or osteoporosis (with low-dose oral bisphosphonates) may have been as low as 1 person in 100,000 person-years of exposure. Things that would increase a person's risk of developing osteonecrosis of the jaw include: (1) Head or neck irradiation, (2) Trauma, (3) Periodontal disease, (4) Local cancer malignancy, (5) Chemotherapy, (6) Glucocorticoid (corticosteroid) therapy, (7) Old age, (8) Female gender, and (9) Intravenous bisphosphonate administration instead of oral administration. Nearly one-third of all victims of osteonecrosis of the jaw reported having a history of glucocorticoid use. More than two-thirds of all victims reported a tooth extraction or other surgical or invasive dental procedure as the inciting event which triggered their osteonecrosis of the jaw. In conclusion, my advice to those who have elected to treat their osteopenia or osteoporosis with bisphosphonates is: (1) Minimize your risk of developing osteonecrosis of the jaw by finishing all of your dental work before beginning treatment, and (2) Even though intravenous administration increases your risk of developing osteonecrosis of the jaw when compared to oral administration, go with intravenous Boniva (ibandronate) injected once every 3 months or intravenous Reclast (zoledronic acid) injected once every 1 year because recent studies indicate that the less frequently a bisphosphonate is administered, the more likely that the patient will tolerate the drug and agree to keep on receiving the drug and happily go on to reduce future fractures by about 50%. Remember that about half of all people will decide to discontinue treatment with bisphosphonates because of substantial side effects. The following 14 PubMed studies discuss bisphosphonate-related osteonecrosis of the jaw: http://www.ncbi.nlm.nih.gov/pubmed/18767452 http://www.ncbi.nlm.nih.gov/pubmed/19371813 http://www.ncbi.nlm.nih.gov/pubmed/19286860 http://www.ncbi.nlm.nih.gov/pubmed/18447663 http://www.ncbi.nlm.nih.gov/pubmed/17599853 http://www.ncbi.nlm.nih.gov/pubmed/18528958 http://www.ncbi.nlm.nih.gov/pubmed/18403302 http://www.ncbi.nlm.nih.gov/pubmed/19484166 http://www.ncbi.nlm.nih.gov/pubmed/19478642 http://www.ncbi.nlm.nih.gov/pubmed/19536938 http://www.ncbi.nlm.nih.gov/pubmed/18501224 http://www.ncbi.nlm.nih.gov/pubmed/19371819 http://www.ncbi.nlm.nih.gov/pubmed/19446234 http://www.ncbi.nlm.nih.gov/pubmed/18201600 The following PubMed study says that if you develop osteonecrosis of the jaw, there is only an 18% chance that it will completely heal and a 52% chance that it will only partially heal with long-term antibiotic therapy: http://www.ncbi.nlm.nih.gov/pubmed/19304045 Finally, the following June, 2009 Pubmed study says Reclast (zoledronic acid) substantially outperformed the other 3 bisphosphonates in vertebral fracture prevention: http://www.ncbi.nlm.nih.gov/pubmed/19530978





Add to the discussion